FARAN · STERILE CMO
Purpose-built sterile drug product capabilities in Tripolis, Greece, from aseptic filling to inspection, device assembly and final packaging.
Planned isolator processing environment
Planned PFS & cartridge units / year
Planned manufacturing batch sizes
Target operational readiness
OUR CMO OFFERING
A new sterile drug product facility, purpose-built for pharmaceutical and biotech partners. From compounding and aseptic filling to inspection, device assembly and final packaging.
Planned capabilities · Target readiness Q4 2027Ready-to-use formats on an Optima nest filling line. Isolator-based processing for sterile liquid drug products.
Planned liquid and freeze-dried vial capabilities, with automated loading and unloading of the freeze dryer.
Automatic visual inspection, leak testing and device assembly, connected to labeling, cartoning and serialization.
Capabilities and capacities are design targets from the May 2026 presentation, not a statement of current production or regulatory approval. Product suitability and available capacity require project-specific confirmation.
THE TECHNICAL PICTURE
| Capability | Prefilled syringes & cartridgesCORE PLANNED LINE | Vials & lyophilizationSECOND PHASE |
|---|---|---|
| Presentation | Ready-to-use prefilled syringes & cartridges | Liquid & freeze-dried vials |
| Container sizes | PFS: 1–20 mL · Cartridges: 1–10 mL | Vials: 1–100 mL |
| Planned line speed | Up to 36,000 units / hour · 10 needles | Up to 18,000 vials / hour |
| Planned annual capacity | 60 million units | 30 million vials, including 4 million freeze-dried |
| Batch size | 100–750 L | 100–750 L |
| In-process control | Selectable 0–100% IPC | 100% IPC |
| Filling mechanism | Rotary piston & peristaltic pumps | Rotary piston & peristaltic pumps |
| Product handling | High viscosity · Nitrogen gassing · Vacuum stoppering | High viscosity · Nitrogen gassing |
| Design potency band | Up to OEB 3 | Up to OEB 3 |
BUILT FOR WHAT COMES NEXT
Our new facility in Tripolis brings production, quality control laboratories, microbiology and warehousing together on a 36,000 m² site.
QUALITY, DESIGNED IN
The facility is being designed for EU GMP Annex 1 and FDA compliance, with isolator technology, automation and integrated quality control at the center of the manufacturing approach.
Design intent — not a claim of GMP certification or FDA approval.Independent aseptic suites, dedicated compounding areas and integrated QC and microbiological laboratories.
Planned automatic visual inspection and high-voltage leak detection (HVLD), with a dedicated vial inspection line in the second phase.
Plunger rods, backstops, safety devices, pen and autoinjector components, followed by labeling, cartoning, case packing, serialization and aggregation.
LET’S BUILD THE NEXT CHAPTER
Discuss your sterile drug product, presentation format, manufacturing scale and timeline with FARAN.
Discuss your project5 Achaias & Troizinias
Nea Kifisia, 145 64, Greece
Tripolis, Greece
